Born: 1950 Title: Member of the Board since 2018, Chairman of the Board since 2021. Former CEO of Medivir AB.
Education: Pharmacist and Ph.D.
Background: Senior positions in major pharmaceutical and biotech companies for over 30 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public, multibillion dollar company. In the 1990s, he held senior positions at Astra AB, prior to which he was a Professor of Organic Chemistry at Uppsala University.
Other directorships: Member of the Board of Active Biotech.
Shares in Medivir: 1,000,000 ordinary shares.
Born: 1973.
Title: Member of the Board since 2024.
Education: Ph.D. in Clinical Immunology from Uppsala University.
Background: More than 25 year’s academic drug development experience within immune oncology and is adjunct Professor of immunotherapy at Uppsala University. She is the CEO of Lokon Pharma since 2012 and a scientific advisor at venture cap Nexttobe. Further, she has >10 year’s board experience from privately owned biotech’s such as Chemilia, Bioimics and the public company Hansa Biopharma.
Other directorships: Chairperson of the Board of Repos Pharma. Member of the Board of Lokon Pharma.
Shares in Medivir: 6,309 ordinary shares.
Born: 1963.
Title: Member of the Board since 2024.
Education: PhD from Karolinska Institutet/MEB with a focus on statistics, MScs in pharmacy and mathematical statistics.
Background: Broad experience from drug development, especially regulatory affairs, from Regulatory Authorities, pharmaceutical companies and consultancy. Founder of the consulting company SDS Life Science which offers expert services within drug development and statistics. Great interest in the design of clinical studies and communication with authorities.
Other directorships: Member of the Boards of MedCap AB, Akiram Therapeutics, Attgeno AB and Lett Renovering AB.
Shares in Medivir: 0.